Pharmaceuticals, Biotechnology & Life Sciences

CEO Ceesay Abraham sells 18,921 Rapport Therapeutics shares at $49.57, signaling disciplined insider strategy as the stock hits a $51.38 52‑week high.

Insightful analysis of Evogene’s insider buying shows management confidence in its AI‑driven drug‑discovery platform and a potential short‑term rally ahead of Q2 earnings.

CEO Kersten Geert’s recent buy of 100k CEL‑SCI shares signals confidence amid volatility, offering investors insight into the company’s future.

Insider buying at EXOZYMES signals leadership confidence—CEO and CCO purchase 19,612 shares, hinting at a rebound and upcoming investor summit.

ExoZymes insider Korman Tyler Paz’s August 19 purchase signals confidence, aligning RSU vesting with upcoming Investor Summit and boosting investor interest.

Explore Longeveron’s 1‑for‑10 reverse split and CFO’s 300k RSU grant, revealing management’s long‑term focus amid a bearish market mood.

Insider trades at OMEROS reveal disciplined buying‑selling strategy, boosting confidence in the company’s valuation and future prospects.

Allogene Therapeutics insider sale: 29,697 shares sold by SVP Douglas Martin as a sell‑to‑cover event. Investors learn the trade is routine, may slightly dampen momentum but signals strong leadership confidence in Allogene’s CAR‑T pipeline and long…

Insider trading at United Therapeutics shows CEO Martine Rothblatt’s disciplined option plan, boosting confidence in ralinepag’s launch and long‑term growth.

Insider buying spurs hope for NewAmsterdam Pharma: Kastelein’s recent share surge hints at a breakthrough, but R&D costs and a negative P/E warn of risk.